• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2023, Vol. 40 ›› Issue (2): 178-181.

• 药品评价 • 上一篇    下一篇

静脉注射免疫球蛋白联合环孢素对高耐药风险川崎病的疗效研究

     熊建兵, 刘苗   

  1. 广州市花都区妇幼保健院(胡忠医院)儿科, 广东 广州 510800
  • 收稿日期:2022-11-14 修回日期:2023-03-07 出版日期:2023-04-28 发布日期:2023-04-28
  • 基金资助:
    医疗卫生一般科研专项(项目名称:静脉注射免疫球蛋白联合环孢素对高耐药风险川崎病的治疗效果研究;项目编号:21-HDWS-106)

Intravenous Immunoglobulin Combined with Cyclosporine on Kawasaki Disease with High Risk of Drug Resistance Efficacy Study

  1. Department of Pediatrics, Huadu District Maternal and Child Health Hospital(Huzhong Hospital), Guangzhou, Guangdong 510800, China
  • Received:2022-11-14 Revised:2023-03-07 Online:2023-04-28 Published:2023-04-28

摘要: 目的:分析高耐药风险川崎病患儿采取静脉注射免疫球蛋白联合环孢素治疗的价值。方法:选取本院2021年5月至2022年7月收治的50例川崎病患儿,随机原则分对照组(行静脉注射免疫球蛋白)与研究组(行静脉注射免疫球蛋白联合环孢素治疗),对比效果。结果:研究组临床症状改善时间短于对照组,P<0.05;研究组炎症指标低于对照组,P<0.05;研究组免疫球蛋白水平高于对照组,P<0.05;研究组不良反应发生率低于对照组,P<0.05;研究组治疗费用及住院时间低于对照组,P<0.05。结论:临床在治疗高耐药风险川崎病患儿时,利用静脉注射免疫球蛋白联合环孢素治疗效果较佳,能够缩短患儿痊愈时间,同时改善患儿免疫球蛋白水平与炎症指标,可为临床用药提供参考。

关键词: font-size:medium, ">静脉注射免疫球蛋白;环孢素;高耐药风险;川崎病;治疗效果

Abstract: Objective:To analyze the value of intravenous immunoglobulin combined with cyclosporin treatment in children with Kawasaki disease at high drug resistance risk. Methods:50 children with Kawasaki disease admitted to our hospital from July 2021 to May 2022 were randomly divided into the control group(intravenous immunoglobulin) and the study group(intravenous immunoglobulin combined with cyclosporine) to compare the effects. Results: The improvement time of clinical symptoms in the study group was shorter than that in the control group(P<0.05). The inflammatory index in the study group was lower than that in the control group(P<0.05); The level of immunoglobulin in the study group was higher than that in the control group(P<0.05). The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05). The treatment cost and hospital stay in the study group were lower than those in the control group(P<0.05). Conclusion: In the treatment of children with Kawasaki disease at high risk of drug resistance, intravenous immunoglobulin combined with cyclosporine has a better effect, which can shorten the recovery time of children, and improve the immunoglobulin level and inflammation index of children.

Key words: font-size:medium, ">Intravenous immunoglobulin; Cyclosporin; High drug resistance risk; Kawasaki disease; Treatment effect

中图分类号: